Phase II study of bevacizumab combined with oral leucovorin plus UFT for elderly patients with metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 21 days every 28 days. Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized
创建时间：
2008-10-15
